AMGEN - Dynamic Strategies in Place for Global Expansion of Innovative Drugs and Biosimilars = Growth Drivers
Amgen (AMGN) began 2013 on a positive note outlining long-term (post-2015) growth strategies through new product launches, global expansion, and entering the global biosimilar space with new partners and ventures. Unexpected setback to Omontys (peginesatide, Affymax/Takeda) is a positive for AMGN. AMGN aims to deliver ~$1.5b in sales with the future expansion in Japan and China and in other emerging markets by 2015-16. A promise to deliver profits through improved operational efficiency and dividend growth is compelling enough to remain.… For more details, please read our report released on 26th Feb. 2013, titled, “Amgen - Dynamic Strategies in Place for Global Expansion of Innovative Drugs and Biosimilars = Growth Drivers”.
